ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals

News   Nov 26, 2015

 
ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals
 
 
 

RELATED ARTICLES

Modified Form of Botox Could Replace Opioids as Treatment for Chronic Pain

News

A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.

READ MORE

Novel Therapeutic Target for Breast Cancer

News

Research has shown for the first time that a tiny piece of RNA deregulates energy metabolism, an emerging hallmark of cancer. The finding identifies a new target for therapeutic intervention in breast cancer.

READ MORE

Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain Circumstances

News

A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy